IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
February 1, 2023
Biotechnology
-
-
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
February 1, 2023
-
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer’s Disease (AD) Patients
January 31, 2023
-
Silo Pharma Announces Stock Repurchase Program
January 31, 2023
-
First Wave BioPharma to Present at the BIO CEO & Investor Conference
January 30, 2023
-
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
January 25, 2023
-
First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
January 25, 2023
-
First Wave BioPharma to Present at Sequire Biotechnology Conference
January 24, 2023
-
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
January 24, 2023
-
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
January 23, 2023
-
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
January 23, 2023
-
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
January 23, 2023
-
Coeptis Exploring Cell Therapies
January 16, 2023
-
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
January 16, 2023
-
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
January 13, 2023
-
First Wave BioPharma Announces Results of Special Meeting of Stockholders
January 13, 2023